INS and diabetic kidney disease: Among the drugs currently being tested as adjuncts to insulin therapy in randomized clinical trials (RCTs), sodium glucose co-transport-2 (SGLT2) inhibitors appear promising because they are unique and independent of the mechanism of action of insulin.[4] Overall, SGLT2 inhibitors significantly improve major cardiometabolic parameters (hemoglobin A1c, fasting glucose, blood pressure, lipid distribution, body weight) and are expected to be successful in cardiovascular disease and diabetic kidney disease.